COMMUNIQUÉS West-GlobeNewswire

Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20
23/01/2024
NEW YORK, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, [...]
Grow Up Conference & Expo Announces Top 50 Cannabis Leaders in Canada Ahead of CannaVision '24 Executive Summit
23/01/2024
Leading cannabis event company celebrates national leaders and launches an exclusive gathering for decision-makers in the global arena Toronto, ON, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Grow Up Conference & Expo (“Grow [...]
A Cut Above: RIFF Cannabis Brand Expands Its Diamond Collection With New THCA ‘Liquid Diamond’ Vapes
23/01/2024
New RIFF Cannabis Collection Includes Diamond-Infused Multi-Packs of Pre-Rolls and Blunts TORONTO, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading [...]
ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP
23/01/2024
BAUDETTE, Minn., Jan. 23, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Pentoxifylline Extended-Release (ER) Tablets, USP 400mg. ANI’s [...]
CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics
23/01/2024
Collaboration to accelerate research to determine role of GBA gene CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner [...]
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2023
23/01/2024
Company Announcement Net sales of DARZALEX ® in 2023 totaled USD 9,744 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; January 23, 2024 – Genmab A/S ( [...]
CDR-Life Announces FDA Clearance of IND Application for CDR404 for Treatment of Solid Tumors
23/01/2024
First-of-its-kind, antibody-based, bivalent and bispecific MAGE-A4 T-cell engager ZURICH, Switzerland, Jan. 23, 2024 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced the clearance of an Investigational New Drug (IND) [...]
HEPHAISTOS-Pharma secures a €2 million seed round with xista science ventures, Foundation Fournier-Majoie and Noshaq
23/01/2024
HEPHAISTOS-Pharma secures a €2 million seed round with xista science ventures, Foundation Fournier-Majoie and Noshaq 1st institutional round for HEPHAISTOS-Pharma, getting on track to bring its lead product ONCO-Boost [...]
HEPHAISTOS-Pharma sécurise un tour de table de €2 millions avec xista science ventures, la Fondation Fournier-Majoie et Noshaq
23/01/2024
HEPHAISTOS-Pharma sécurise un tour de table de €2 millions avec xista science ventures, la Fondation Fournier-Majoie et Noshaq 1er tour institutionnel pour HEPHAISTOS, en bonne voie pour amener son produit phare ONCO- [...]
German Pain Association (DGS) and Pharmaceutical Company Avextra Join Forces to Launch Their New Study OCEAN
23/01/2024
Avextra, the German pharmaceutical company focused on Cannabis-Based Medicines (CBM) and the German Pain Association (DGS), the leading physicians’ society dedicated to chronic pain therapy, jointly announces their [...]
Ex dividend NOK 0.75 today
23/01/2024
The shares in Vistin Pharma ASA will be traded ex dividend NOK 0.75 as from today, 23.01.2024.
Change in Orion Group Executive Management Board – René Lindell appointed Chief Financial Officer of Orion
23/01/2024
ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES BOARD / MANAGEMENT / AUDITORS 23 JANUARY 2024 at 9.00 EET Change in Orion Group Executive Management Board – René Lindell appointed Chief Financial Officer of Orion [...]
Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis
23/01/2024
Pluri to leverage its proprietary 3D technology platform to develop cell-based products for the coffee industry under its new business vertical PluriAgtech The rapidly growing $130 billion coffee industry is at risk as [...]
Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
23/01/2024
Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline Acquisition supports Sanofi’s portfolio growth strategy and complements 30-year heritage [...]
Communiqué de presse : Sanofi va acquérir Inhibrx, Inc. et ajouter à son portefeuille Maladies rares un actif pour le traitement du déficit en alpha-1-antitrypsine, potentiellement le meilleur de sa classe pharmacothérapeutique
23/01/2024
Sanofi va acquérir Inhibrx, Inc. et ajouter à son portefeuille Maladies rares un actif pour le traitement du déficit en alpha-1-antitrypsine, potentiellement le meilleur de sa classe pharmacothérapeutique Cette [...]
Sequana Medical announces DSMB approval to start randomized MOJAVE cohort – US Phase 1/2a study of DSR® 2.0 for treatment of heart failure
23/01/2024
PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 23 January 2024, 07:00 am CET DSMB i rates DSR 2.0 as safe following review of data from non-randomized cohort Data from non-randomized cohort confirms dramatic [...]
iThemba LABS ready to start production of Strontium-82 and Germanium-68 using IBA Cyclone® 70
23/01/2024
Successful completion of contractual site acceptance tests, with 70 MeV cyclotron now fully operational Louvain-la-Neuve, Belgium, January 23, 2024 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in [...]
iThemba LABS prêt à produire du strontium-82 et du germanium-68 avec un Cyclone® 70 d'IBA
23/01/2024
Cyclotron de 70 MeV désormais pleinement opérationnel suite à la finalisation des tests d’acceptation. Louvain-la-Neuve, Belgique, le 23 janvier 2024 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des [...]
BioSenic files for additional patent protection following new clinical evidence of efficacy for JTA-004 in osteoarthritis
23/01/2024
PRESS RELEASE – INSIDE INFORMATION Following a post-hoc analysis of a Phase 3 trial demonstrating pain relief in patients with severe knee osteoarthritis, Biosenic applied for an international patent to support the [...]

Pages